Welcome Back
Click “Sign in” to agree to Cointime’s Terms of Service and acknowledge that Cointime’s Privacy Policy applies to you.
Join CoinTime
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">Terms of Service</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">Privacy Policy</a> applies to you.
Sign in with email
Sign up with email
Your email
Check your inbox
Click the link we sent to to sign in.
Click the link we sent to to sign up.
OncoSTING
company
About
OncoSTING is developing novel bladder cancer therapies by harnessing the potency of standard BCG immunotherapy
- 1 - 10
Details
- Last Funding Type
- Grant
- Last Funding Money Raised
- $256K
- Industries
- Health Care
- Founded date
- Jan 1, 2018
- Number Of Employee
- 1 - 10
- Operating Status
- Active
OncoSTING, located in Baltimore, is developing novel bladder cancer therapies that work by combining the potency of standard BCG immunotherapy with long-lived delivery of potent STING agonists. (JHU)
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
$256K
OncoSTING has raised a total of
$256K
in funding over 2 rounds. Their latest funding was raised on
Jun 1, 2022 from a Grant round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Jun 1, 2022 | Grant | $256K | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
1
OncoSTING is funded by 1 investors.
National Science Foundation
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
National Science Foundation
|
— | Grant |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
